Back

Use and costs of P2Y12 inhibitors after myocardial infarction in germany and the US

31 August 2026 (12:15 - 12:40)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes: local deposition vs. systemic treatment Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Fabian Mueller

Munich (Germany)

2 More presentations in this session

Presentation thumbnail
One-year clinical outcomes of aspirin versus indobufen in patients with NSTEMI: a multicenter retrospective cohort study
Doctor H. Zhang (Tianjin, CN)
Abstract
Presentation thumbnail
Immediate versus staged complete revascularization in multivessel acute coronary syndromes: a comparative meta-analysis of efficacy and safety in STEMI and NSTE-ACS
Doctor R. Khowaja (Karachi, PK)
Abstract

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes: local deposition vs. systemic treatment

The Event

Event poster

ESC Congress 2026

31 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Budget impact analysis of antiplatelet therapy with cangrelor in patients with acute coronary artery disease undergoing percutaneous coronary intervention in Belgium
13 March 2021
thumbnail
Congress Presentation
Persistence to guideline-based therapy newly prescribed after a hospitalization for heart failure. Data from two large cohorts in the US and Germany.
20 May 2023
thumbnail
Congress Presentation
Is there an inter-manufacturer difference in generic clopidogrel response?
26 August 2022
thumbnail
Congress Presentation
Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources